Compare Biogen Inc (BIIB) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Biogen Inc trades at $193.66 (market cap $28.34B), while Vanguard Total Stock Market Index Fund ETF trades at $372.29. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | VTI | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | — |
52-Week High | $216.63 | $374.36 |
52-Week Low | $122.68 | $305.74 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
VTI trades at $369.78, down 0.78% on the day, with a bullish technical signal supported by moving averages. The ETF provides comprehensive U.S. market exposure with over 3,400 stocks and an ultra-low 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and strong long-term performance history averaging nearly 10% annual returns over 25 years.
VTI offers diversified U.S. equity exposure with minimal costs, though its performance remains tied to broader market volatility. Key risks include economic downturns and interest rate sensitivity, while institutional adoption and positive media sentiment support its long-term appeal for core portfolio holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
